Mr. Bienaimé retired in December 2023 as Chairman and Chief Executive Officer of BioMarin, and currently serves as a member of the company’s Board of Directors. During his 18 years as CEO, Mr. Bienaimé helped lead the company through a period of significant growth, overseeing the approval of seven new medicines, including the company’s globally leading enzyme replacement therapies and the recent introductions of VOXZOGO® for achondroplasia and ROCTAVIAN™, the world’s first gene therapy for hemophilia A. During his tenure, Mr. Bienaimé led the growth of the business from annual revenues of approximately $26 million when he started to more than $2 billion. He also oversaw a major expansion of BioMarin’s workforce, from about 300 employees only in the United States when he joined the company to more than 3,000 people in almost 80 countries around the world at the time of his retirement.

Prior to BioMarin, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership from 2002 to 2005, Genencor’s revenues and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of more than $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of SangStat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corp. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals, where he was responsible the U.S. launch of Lovenox for the prevention of pulmonary embolism and treatment of unstable angina and global launch of Taxotere for breast and lung cancers. Earlier in his career, he worked at Genentech, Inc., where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.

Mr. Bienaimé currently serves on the boards of Incyte Corp., the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO). He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.